The Latest Breaking News from Roche

Pharmaceutical companies including Novartis and Roche have teamed up with global cancer organizations in an alliance aimed at getting more oncology medications to poorer countries. Currently, fewer than 50% of the cancer drugs on the World Health Organization's (WHO) essential medicines list are available in low and middle income countries,…

Health crises and emergencies such as Covid-19 have brought into sharp focus the critical need for preparedness. The unprecedented pandemic has led to a dynamically changing environment across the healthcare industry, posing challenges that call for innovative solutions.

The U.S. Medicare program’s decision to tightly limit coverage for the first drug meant to slow the course of Alzheimer’s disease has raised the stakes for companies trying to make the next one.

AstraZeneca Plc (NASDAQ:AZN) shared new and prolonged follow-up results from the Phase 3 CHAMPION-MG trial open-label extension (OLE) of Ultomiris (ravulizumab-cwvz) in generalized myasthenia gravis (gMG). Ultomiris demonstrated long-term efficacy, with improvements in activities of daily living, muscle strength, and quality of life sustained through 60 weeks. Ultomiris was also well tolerated throughout…

The FDA has granted priority review to Roche Holdings AG's (OTC:RHHBY) Actemra/RoActemra (tocilizumab) for COVID-19 in hospitalized adults. "If approved, Actemra/RoActemra would be the first U.S. FDA-approved immunomodulator for treating COVID-19 in hospitalized patients," Roche said. The Compay also added that more than 1 million people hospitalized with COVID-19 had been treated with Actemra/RoActemra…

Here's a roundup of top developments in the biotech space over the last 24 hours.

A highly anticipated new cancer immunotherapy by Roche failed to slow the progression of an aggressive form of lung cancer, the Swiss drug maker said on Wednesday, boding ill for a range of rival drug developers working on similar compounds. The Skyscraper 2 trial was the first to produce results…

At the annual congress of the Muscular Dystrophy Association (MDA), Roche Holdings AG (OTC:RHHBY) announced new data for its spinal muscular atrophy (SMA) drug Evrysdi (risdiplam). Evrysdi is a novel survival motor neuron 2 (SMN2) splicing modifier, licensed from PTC Therapeutics Inc (NASDAQ:PTCT). At the annual MDA event, Roche’s presentations included new three-year data from the…

Roche Holdings AG (OTC: RHHBY) has decided to close out a patent infringement lawsuit against AstraZeneca plc (NASDAQ: AZN), centering around the latter's newly acquired rare disease drug Ultomiris for a